この論文を読む／探す
抄録
前立腺肥大症(BPH)犬の治療薬として開発中のanti-androgen剤であるosaterone acetate(OSA)の,BPH犬5頭に対する前立腺縮小効果を観察した.その結果,OSA 0.2または0.5mg/kgの1週間投与で,投与後1週で前立腺縮小率は平均62.6%であった.しかし,前立腺は投与後平均6ケ月で投与前の大きさに肥大した.以上のことから,OSAはBPHを早期にまた急激に抑制することから,BPH犬への臨床応用が可能であると思われた.
The effects of osaterone acetate (USA), which is an anti-androgen agent being developed as a therapeutic drug for benign prostatic hypertrophy (BPH) in dogs, on the degree of prostatic regression and semen qualities were investigated. Prostatic regression was compared between dogs with and without orchidectomy. Five male beagles aged 5-9 years were used in the experiment. OSA was orally administered at doses of 0.2 mg/kg and 0.5 mg/kg for one week. The prostatic regression rate one week after the end of administration was 62.6% on average. In the orchidectomized group, the mean regression rate one week after orchidectomy was 60.1 %. However, the prostate became enlarged 6 months after administration, compared to the size prior to administration. The above findings suggested that OSA is clinically applicable as a therapeutic drug for BPH in dogs, and inhibits prostatic hypertrophy during the earlyphase.
